BG
Last reporting period 30 Sep, 2023
Updated 18 Sep, 2024
Last price
—
Market cap $B
0.008
Exchange
XNAS - Nasdaq
0.0047 B
Last period Cash and equivalents ,USD
What is Cash and equivalents ?
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
See also BioNexus Gene
Company Analysis
BGLC valuation, rating, competitors, insights and company profile
Eyestock Rating
BGLC financial analysis by Eyestock methodology
Valuation
BGLC valuation using historical relative method
Statements
BGLC Income Statements, Balance Sheet and Cash Flow Statements
Dividends
BGLC dividend yield and annual dividend
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
BioNexus Gene`s Cash and equivalents for the period ended 2023-09-30 are 0.0047 B USD
